INOVIO Added Included In Russell 2000 Index, Effective July 1, 2024

7/1/24 8:04:21 AM ET

Medical/Dental Instruments

Health Care

Get the next $INO alert in real time by email

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This reconstitution became effective after the close of the US equities markets on June 28, 2024.

Get the next $INO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INO

Date	Price Target	Rating	Analyst
5/14/2024	$20.00	Overweight	Stephens
1/25/2024	$4.00	Perform → Outperform	Oppenheimer
11/9/2022		Buy → Hold	Maxim Group
11/1/2022	$2.00	Neutral → Underperform	BofA Securities
7/19/2022	$5.00 → $4.00	Sector Perform	RBC Capital Mkts
5/11/2022		Outperform → Perform	Oppenheimer
3/2/2022	$6.00 → $5.00	Sector Perform	RBC Capital
1/21/2022	$8.00 → $10.00	Underperform → Neutral	B of A Securities

More analyst ratings

$INO
Financials

Live finance-specific insights

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaData showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trialContinued progress on preparing regulatory submissions for INO-3107All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025PLYMOUTH MEETING, Pa., Nov. 14, 2024 /PRNewswire/ --
11/14/24 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with RRP. We expect all non-device related elements of our BLA package to be
8/8/24 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.i
7/25/24 8:00:00 AM ET
$INO
Medical/Dental Instruments
Health Care

$INO
Leadership Updates

Live Leadership Updates

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le
7/2/24 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic
6/27/22 8:00:00 AM ET
$INO
Medical/Dental Instruments
Health Care
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles. Dr. Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr. Shea as a director following INOVIO'
5/10/22 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaData showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trialContinued progress on preparing regulatory submissions for INO-3107All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025PLYMOUTH MEETING, Pa., Nov. 14, 2024 /PRNewswire/ --
11/14/24 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UKPLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect
11/13/24 8:00:00 AM ET
$INO
Medical/Dental Instruments
Health Care
INOVIO to Present at Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enric
11/6/24 4:05:00 PM ET
$INO
Medical/Dental Instruments
Health Care

INOVIO Added Included In Russell 2000 Index, Effective July 1, 2024

Chat with this insight

Recent Analyst Ratings for $INO

$INO SEC Filings

Inovio Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Inovio Pharmaceuticals Inc.

SEC Form 424B5 filed by Inovio Pharmaceuticals Inc.

$INO Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target

Inovio Pharmaceuticals shares are trading higher after the company announced that INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway.

INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis

$INO Financials

Live finance-specific insights

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

$INO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stephens initiated coverage on Inovio Pharma with a new price target

Inovio Pharma upgraded by Oppenheimer with a new price target

Inovio Pharma downgraded by Maxim Group

$INO Leadership Updates

Live Leadership Updates

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

$INO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$INO Press Releases

Fastest customizable press release news feed in the world

Chief Medical Officer Sumner Michael John converted options into 2,917 shares, increasing direct ownership by 55% to 8,219 units (SEC Form 4)

SEC Form 4 filed by Zoth Lota S.

SEC Form 4 filed by Shepard Jay

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

INOVIO to Present at Upcoming Scientific Conferences

$INO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$INO

$INO
SEC Filings

$INO
Market Insights

$INO
Financials

$INO
Analyst Ratings

$INO
Leadership Updates

$INO
Insider Trading

$INO
Press Releases

$INO
Large Ownership Changes